Germany's BioNTech SE said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialise its cancer antibody drug candidate.
OncoC4 will get a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties.
The companies said they will co-develop the candidate, ONC-392, as a monotherapy or as a combination therapy in various cancer indications.
A late-stage trial for the drug has been planned for this year, the companies said.
Vaccine against cervical cancer to be included by mid-2023: NTAGI chief
Scholarships worth Rs 75 cr misappropriated by institutes in UP: ED
Researchers take closer look at DNA repair scheme for cancer therapy
Hair straightening chemicals associated with uterine cancer risk: Study
Cancer screening, treatment affected due to Covid, picking up again: Govt
To calm turmoil, UBS to buy Credit Suisse in $3.25 billion rescue deal
New York Community Bank to buy failed Signature Bank in a $2.7 bn deal
Credit Suisse's 9,000 job cuts are foretaste of UBS takeover amid crisis
Credit Suisse tells staff bonuses will still be paid amid UBS takeover
ADP, GMR Airports infrastructure to merge joint venture with GMR
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)